{'fraction_non_alphanumeric': 0.01778242677824268, 'fraction_numerical': 0.0031380753138075313, 'mean_word_length': 5.985401459854015, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Symptom Progression in Peripheral Artery Disease: Sounding the Alarm for Cardiovascular Risk.

Peripheral artery disease (PAD) is a malignant atherosclerotic phenotype associated with a heightened risk of cardiovascular events, limb-related events, and death.1 Many patients with PAD have additional comorbidities, such as diabetes mellitus or atherosclerosis in additional vascular beds, which further amplify this risk.2 In the last 2 decades, the landscape of PAD management has dramatically changed with the emergence of new risk factor modifying drugs and advances in endovascular therapies specifically targeting this highrisk patient population. Understanding how disease progression impacts the full spectrum of cardiovascular and limb outcomes is critical to help identify patients who will benefit from escalation of their secondary prevention therapies, some of which, such as antiplatelet and antithrombotic agents, also increase bleeding risk.